SNGXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Soligenix, Inc. hold a median 12-month price target of $1.38 — +281.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 14 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Soligenix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (7): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SNGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +281.3% from it.
Of the 10 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 July 2025 | Alliance Global Partners | Maintains | Buy | $10 → $6.00 |
| 4 Dec 2020 | B. Riley FBR | Initiates | Buy | — |
| 4 Dec 2020 | B. Riley Securities | Initiates | Buy | $4.00 |
| 28 July 2020 | Dawson James | Downgrade | Neutral | $3.00 → $2.00 |
| 31 Jan 2018 | H.C. Wainwright | Downgrade | Neutral | — |
| 31 Jan 2018 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 14 Aug 2017 | Maxim Group | Maintains | Buy | $4.00 → $5.00 |
| 17 July 2017 | H.C. Wainwright | Initiates | Buy | — |
| 17 July 2017 | HC Wainwright & Co. | Initiates | Buy | — |
| 7 Sept 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNGX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, Soligenix, Inc. returned −87.7% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 68% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Soligenix, Inc. has a market value of $7.8M and an enterprise value of −$1.7M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$11.0M.
Free cash flow in the twelve months to 31 Mar 2026: −$10.8M.
Trailing P/E: −0.2×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Soligenix, Inc. employs 13 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Soligenix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Soligenix, a biopharmaceutical company developing products to treat rare diseases with unmet medical need, announced its recent updates and financial results for the quarter ended June 30, 2026.
Why it matters — This announcement provides Soligenix watchers with an update on the company's operations and its financial position for the second quarter of 2026.
The 1 Wall Street analysts covering Soligenix, Inc. have a median 12-month price target of $1.38, with estimates ranging from $1.25 to $1.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Soligenix, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Soligenix, Inc. 25 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Sept 2026, Soligenix, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +281.3% from the last close, and Ticker Nerd's factor model ranks Soligenix, Inc. 25 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Soligenix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.25 to $1.5 over the next 12 months.
Soligenix, Inc. returned -87.7% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases and other conditions with unmet medical needs.
The most recent item we track (PRNewsWire, 7 Aug 2026): "Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results". Soligenix, a biopharmaceutical company developing products to treat rare diseases with unmet medical need, announced its recent updates and financial results for the quarter ended June 30, 2026.
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases and other conditions with unmet medical needs. Its core business is organized into two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops treatments for orphan and inflammatory diseases, including cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease. The Public Health Solutions segment works on vaccines and therapeutics for biodefense and infectious disease threats, including ricin exposure, Ebola, Marburg, and other emerging viral infections. Soligenix Inc. plays a niche role in the healthcare market by targeting areas where treatment options remain limited, combining rare disease development with medical countermeasure research.
CEO Dr. Christopher J. Schaber Ph.D. · 13 employees · United States · https://www.soligenix.com
